Glucagon‐like peptide‐1 receptor expression in the human eye

Semaglutide is a human glucagon‐like peptide‐1 (GLP‐1) analogue that is in development for the treatment of type 2 diabetes. In the pre‐approval cardiovascular outcomes trial SUSTAIN 6, semaglutide was associated with a significant increase in the risk of diabetic retinopathy (DR) complications vs p...

Descripción completa

Detalles Bibliográficos
Autores principales: Hebsgaard, Josephine B., Pyke, Charles, Yildirim, Emre, Knudsen, Lotte B., Heegaard, Steffen, Kvist, Peter H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2018
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6099507/
https://www.ncbi.nlm.nih.gov/pubmed/29707863
http://dx.doi.org/10.1111/dom.13339

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6099507/
https://www.ncbi.nlm.nih.gov/pubmed/29707863
http://dx.doi.org/10.1111/dom.13339

Ejemplares similares